{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:13:37Z","timestamp":1788502417852,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd014544.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000}}],"reference-count":241,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014544.pub3","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:17:25Z","timestamp":1774358245000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B"],"prefix":"10.1002","volume":"2026","author":[{"given":"Omotola O","family":"Olasupo","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noella","family":"Noronha","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact (HEI); McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Ansel","sequence":"additional","affiliation":[{"name":"Synteract; Philadelphia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4074","authenticated-orcid":false,"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"10.1002\/14651858.CD014544.pub3-BIB0001|cit1","unstructured":"A phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/07\/014698"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0002|cit2","unstructured":"A study of fitusiran (ALN-AT3SC) in hemophilia A and B patients without inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-001464-11-IE"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0003|cit3","unstructured":"A study of fitusiran (ALN-AT3SC) in hemophilia A and B patients without inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-001464-11-NL"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0004|cit4","unstructured":"A study of fitusiran (ALN-AT3SC) in severe hemophilia a and b patients without inhibitors clinicaltrials.gov\/show\/NCT03417245"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0006|cit6","unstructured":"A Phase 3 study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/06\/014682"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0007|cit7","unstructured":"A Study of fitusiran (ALN-AT3SC) in hemophilia A and B patients with inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-001463-36-BG"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0008|cit8","unstructured":"A study of fitusiran (ALN-AT3SC) in severe hemophilia a and b patients with inhibitors clinicaltrials.gov\/ct2\/show\/NCT03417102"},{"issue":"10386","key":"10.1002\/14651858.CD014544.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Astermark J Angchaisuksiri P Benson G Castaman G Chowdary P Eichler H Longer-term efficacy and safety of concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: Results from the main and extension parts of concizumab phase 2 trials Research and Practice in Thrombosis and Haemostasis 2021 https:\/\/dx.doi.org\/10.1002\/rth2.12589","DOI":"10.1002\/rth2.12589"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD014544.pub3-BIB0011|cit11","first-page":"1","article-title":"Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in hemophilia A and hemophilia A\/B with inhibitors: Phase 2 trial results","volume":"3","author":"Astermark","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014544.pub3-BIB0012|cit12","first-page":"1","article-title":"Subcutaneous prophylaxis with the anti-TFPI monoclonal antibody concizumab in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"3","author":"Astermark","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0013|cit13","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000510-30-ES"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1182\/blood-2021-152257","article-title":"Improvement in health-related quality of life measures after long-term, daily, subcutaneous concizumab prophylaxis in patients with hemophilia a\/b with and without inhibitors: Results from the main and extension parts of phase 2 clinical trials","volume":"138","author":"Faller","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Hummelshoj Landsy L Castaman G Cepo K Lenting P Oldenburg J Immunogenicity in the concizumab phase 2 clinical trials: Clinical impact of antidrug antibodies Research and Practice in Thrombosis and Haemostasis 2021 https:\/\/dx.doi.org\/10.1002\/rth2.12591","DOI":"10.1002\/rth2.12591"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2019-122827","article-title":"Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results","volume":"134","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2019-122827","article-title":"Concizumab subcutaneous prophylaxis improves health-related quality-of-life measures in patients with congenital hemophilia with inhibitors: phase 2 trial results","volume":"134 Suppl 1","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Mancuso M Skov Neergaard J Cepo K Porstmann T Treatment experience in hemophilia patients with and without inhibitors on concizumab prophylaxis: Hemo-TEM results from the phase 2 explorer4 & 5 studies Research and Practice in Thrombosis and Haemostasis 2022 https:\/\/dx.doi.org\/10.1002\/rth2.12787","DOI":"10.1002\/rth2.12787"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0019|cit19","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in haemophilia a and b patients with inhibitors clinicaltrials.gov\/show\/NCT03196284"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood-2019-122809","article-title":"Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood-2019-122809","article-title":"Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with hemophilia A or B with inhibitors: results from explorer4, a phase 2, randomized, open-label, controlled trial","volume":"134 Suppl 1","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"SUPPL 2","key":"10.1002\/14651858.CD014544.pub3-BIB0022|cit22","first-page":"128","article-title":"Safety and longer-term efficacy of concizumab prophylaxis in patients with haemophilia A or B with inhibitors: Results from the extension part of the phase 2 EXPLORER4 trial","volume":"27","author":"Shapiro","year":"2021","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Shapiro A Cepo K Tonder SM Young G Jimenez-Yuste V Safety and efficacy of concizumab prophylaxis following a switch from rFVIIa on-demand treatment: Subanalysis results from the phase 2 explorer4 trial in patients with hemophilia A or B with inhibitors Research and Practice in Thrombosis and Haemostasis 2021 5 SUPPL 2 https:\/\/dx.doi.org\/10.1002\/rth2.12589","DOI":"10.1002\/rth2.12589"},{"issue":"22","key":"10.1002\/14651858.CD014544.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014544.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","article-title":"Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors","volume":"6","author":"Shapiro","year":"2022","journal-title":"Blood Advances"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD014544.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139910","article-title":"Safety and longer-term efficacy of concizumab prophylaxis in patients with hemophilia a or b with inhibitors: Results from the extension part of the phase 2 explorer4 trial","volume":"136","author":"Shapiro","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0027|cit27","first-page":"77","article-title":"Treatment burden and patient preference in patients with haemophilia A or B with inhibitors on concizumab prophylaxis: results from the phase 3 EXPLORER 7 study","volume":"29","author":"Hampton","year":"2023","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0028|cit28","first-page":"S3","article-title":"Concizumab Prophylaxis in Patients with Haemophilia A or B with Inhibitors: Efficacy and Safety Results from the Primary Analysis of the Phase 3 EXPLORER7 Trial","volume":"38","author":"Kaushik","year":"2022","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0029|cit29","first-page":"94","article-title":"Health-related quality of life in patients with haemophilia A or B with inhibitors on concizumab prophylaxis: results from the phase 3 EXPLORER 7 study","volume":"29","author":"Linari","year":"2023","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0030|cit30","first-page":"17","article-title":"Subcutaneous concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results by haemophilia subtype from the EXPLORER t trial","volume":"29","author":"Mathias","year":"2023","journal-title":"Haemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 Trial of Concizumab in Hemophilia with Inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0032|cit32","unstructured":"Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors (Explorer 7) www.clinicaltrials.gov\/show\/NCT04083781"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0033|cit33","first-page":"138","article-title":"Active lifestyle in patients with haemophilia A or B with inhibitors on once-daily subcutaneous concizumab prophylaxis: results from the phase 3 EXPLORER 7 study","volume":"29","author":"Windyga","year":"2023","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0034|cit34","first-page":"724","article-title":"Factor VIII (FVIII) inhibitor testing using a validated chromogenic bethesda assay (CBA) in HAVEN 1 (BH29884), a Phase 3 trial of emicizumab in persons with hemophilia a (PwHA) with inhibitors","volume":"1","author":"Adamkewicz","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0035|cit35","first-page":"129","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: Analyses from the haven 1 study","volume":"181","author":"Callaghan","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjh.15226","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: analyses from the haven 1 study","volume":"181","author":"Callaghan","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"16","key":"10.1002\/14651858.CD014544.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014544.pub3-BIB0038|cit38","first-page":"126","article-title":"Safety and efficacy of emicizumab in persons with haemophilia a with\/without FVIII inhibitors: pooled data from four phase III studies (Haven 1-4)","volume":"27","author":"Callaghan","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-137438","article-title":"Safety and efficacy of emicizumab in persons with hemophilia a with or without fviii inhibitors: pooled data from four phase iii studies (haven 1-4)","volume":"136","author":"Callaghan","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0040|cit40","first-page":"3668","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: analyses from the HAVEN 1 study","volume":"130","author":"Callaghan","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0041|cit41","unstructured":"A phase III study to evaluate the efficacy, safety, and pharmacokinetics of prophylactic RO5534262 versus no prophylaxis in hemophilia a patients with inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-002866-21-ES"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0042|cit42","first-page":"128","article-title":"Surgical experience in two multicentre, openlabel phase 3 studies of emicizumab in persons with haemophilia a with inhibitors (HAVEN 1 and HAVEN 2)","volume":"181","author":"Kruse-Jarres","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V130.Suppl_1.89.89","article-title":"Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)","volume":"130 Suppl 1","author":"Kruse-Jarres","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0045|cit45","first-page":"1071","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with hemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the haven 1 study","volume":"130","author":"Mancuso","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.V130.Suppl_1.1071.1071","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with hemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the haven 1 study","volume":"130","author":"Mancuso","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0047|cit47","first-page":"127","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with haemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study","volume":"181","author":"Mancuso","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0048|cit48","first-page":"127","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with haemophilia a previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the haven 1 study","volume":"181","author":"Mancuso","year":"2018","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0049|cit49","unstructured":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Cilinicaltrials.gov 2015"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0050|cit50","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in hemophilia a participants with inhibitors www.clinicaltrials.gov\/show\/NCT02622321"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD014544.pub3-BIB0051|cit51","first-page":"A6","article-title":"Efficacy, safety and pharmacokinetics (PK) of emicizumab (ACE910) prophylaxis (Px) in persons with haemophilia A with inhibitors (PwHAwl): randomized, multicenter, open-label, phase 3 study (HAVEN 1)","volume":"38","author":"Oldenburg","year":"2018","journal-title":"Hamostaseologie"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1055\/s00034925","article-title":"Efficacy, safety and pharmacokinetics (PK) of emicizumab (ACE910) prophylaxis (Px) in persons with haemophilia A with inhibitors (PwHAwl): randomized, multicenter, open-label, phase 3 study (HAVEN 1)","volume":"38","author":"Oldenburg","year":"2018","journal-title":"H\u00e4mostaseologie"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0056|cit56","first-page":"27","article-title":"Pharmacokinetics (PK), PK\/PD relationships of emicizumab in persons with haemophilia a (PWHA) with inhibitors from adolescent\/adult (HAVEN 1) and paediatric (HAVEN 2) phase 3 studies","volume":"24","author":"Schmitt","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2019-123654","article-title":"Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 haven 3 study experience","volume":"134","author":"Callaghan","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1002\/14651858.CD014544.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014544.pub3-BIB0061|cit61","first-page":"126","article-title":"Safety and efficacy of emicizumab in persons with haemophilia a with\/without FVIII inhibitors: pooled data from four phase III studies (Haven 1-4)","volume":"27","author":"Callaghan","year":"2021","journal-title":"Haemophilia"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD014544.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-137438","article-title":"Safety and efficacy of emicizumab in persons with hemophilia a with or without fviii inhibitors: pooled data from four phase iii studies (haven 1-4)","volume":"136","author":"Callaghan","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0063|cit63","unstructured":"A Study to Evaluate the Effectiveness and Safety of Prophylactic Emicizumab Versus no Prophylaxis in Haemophilia A Patients Without Inhibitors EUCTR 2016"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0064|cit64","unstructured":"A study to evaluate the effectiveness and safety of prophylactic emicizumab versus no prophylaxis in haemophilia a patients without inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000072-17-ES"},{"issue":"7","key":"10.1002\/14651858.CD014544.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/03007995.2020.1744549","article-title":"RE: Reyes A, R\u00e9vil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079\u20132087","volume":"36","author":"Jain","year":"2020","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2018-99-118132","article-title":"Preference for emicizumab over prior factor treatments: results from the HAVEN 3 and HAVEN 4 studies","volume":"132","author":"Jimenez-Yuste","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/hae.14222","article-title":"Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors","volume":"27","author":"Kempton","year":"2021","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/hae.14642","article-title":"Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study","volume":"28","author":"Kiialainen","year":"2022","journal-title":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/jbm.S288283","article-title":"Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"Journal of Blood Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0072|cit72","unstructured":"A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors clinicaltrials.gov\/ct2\/show\/NCT02847637"},{"issue":"S 01","key":"10.1002\/14651858.CD014544.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"SY17","DOI":"10.1055\/s-0039-1680140","article-title":"Emicizumab prophylaxis administered once-weekly or every two weeks provides effective bleed prevention in persons with hemophilia A (PwHA) without inhibitors-results from the phase III HAVEN 3 study","volume":"39","author":"Oldenburg","year":"2019","journal-title":"H\u04d3mostaseologie"},{"issue":"12","key":"10.1002\/14651858.CD014544.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"1","author":"Reyes","year":"2019","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"10.1002\/14651858.CD014544.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"1","author":"Reyes","year":"2019","journal-title":"Current Medical Research and Opinion"},{"issue":"7","key":"10.1002\/14651858.CD014544.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/03007995.2020.1744550","article-title":"Reply: RE: Reyes A, R\u00e9vil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3. Curr Med Res Opin. 2019;35(12): 2079-87","volume":"36","author":"Reyes","year":"2020","journal-title":"Current Medical Research Opinion"},{"issue":"12","key":"10.1002\/14651858.CD014544.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes","year":"2019","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/rth2.12229","article-title":"Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PWHA) with and without inhibitors: update from the haven 3 and haven 4 studies","volume":"3","author":"Skinner","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejps.2014.02.009","article-title":"Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration","volume":"56","author":"Agers\u00f8","year":"2014","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0082|cit82","unstructured":"AKATSUKI Study trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCTs041200037"},{"issue":"22","key":"10.1002\/14651858.CD014544.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMc1712683","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Aledort","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD014544.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMc1909742","article-title":"Deaths associated with emicizumab in patients with hemophilia A","volume":"381","author":"Aledort","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0085|cit85","first-page":"786","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"382","author":"Aledort","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0086|cit86","unstructured":"Study to evaluate the safety, pharmacokinetics and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2011\/11\/002103"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/jbm.S288283","article-title":"Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with Hemophilia A without Inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"Journal of Blood Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0088|cit88","unstructured":"A study of fitusiran in severe hemophilia A and B patients previously receiving factor or bypassing agent prophylaxis (ATLAS-PPX) clinicaltrials.gov\/ct2\/show\/NCT03549871"},{"issue":"11","key":"10.1002\/14651858.CD014544.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"e27886","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort","volume":"1","author":"Barg","year":"2019","journal-title":"Pediatric Blood and Cancer"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a paediatric cohort: real-world data","volume":"1","author":"Barg","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/rth2.12229","article-title":"Evaluating patient and caregiver treatment preferences in hemophilia A using a discrete choice experiment","volume":"3","author":"Benton","year":"2019","journal-title":"RPTH"},{"issue":"21","key":"10.1002\/14651858.CD014544.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/bloodadvances.2020002789","article-title":"The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia","volume":"4","author":"Bertolet","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0095|cit95","unstructured":"The hemophilia inhibitor prevention trial www.clinicaltrials.gov\/show\/NCT04303559"},{"issue":"21","key":"10.1002\/14651858.CD014544.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/bloodadvances.2020002789","article-title":"The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia","volume":"4","author":"Bertolet","year":"2020","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0097|cit97","unstructured":"The hemophilia inhibitor eradication trial www.clinicaltrials.gov\/show\/NCT04303572"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0098|cit98","unstructured":"A study to evaluate overall health, physical activity, and joint outcomes in participants with severe or moderate hemophilia A without Factor VIII inhibitors on emicizumab prophylaxis (Beyond ABR) clinicaltrials.gov\/study\/NCT05181618"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/bjh.16512","article-title":"Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring","volume":"1","author":"Biron-Andreani","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"15","key":"10.1002\/14651858.CD014544.pub3-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1111\/hae.13689","article-title":"Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors","volume":"25","author":"Brophy","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/hae.14082","article-title":"The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia","volume":"26 Suppl 5","author":"Brown","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1056\/NEJMc1916299","article-title":"Emicizumab in hemophilia A","volume":"382","author":"Buckner","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/a-1499-0030","article-title":"Emicizumab dosing in children and adults with hemophilia A: simulating a user-friendly and cost-efficient regimen","volume":"122","author":"Bukkems","year":"2022","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0105|cit105","unstructured":"To study the long-term safety and efficacy of recombinant human coagulation factor IX fusion protein (rFIXFc) in haemophilia B patients trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2012\/05\/002708"},{"issue":"7","key":"10.1002\/14651858.CD014544.pub3-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17474086.2019.1624519","article-title":"Emicizumab for hemophilia A without inhibitors","volume":"12","author":"Cafuir","year":"2019","journal-title":"Expert Review of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"E10-E11","DOI":"10.1002\/ajh.25268","article-title":"Characterization of the impact of prior ITI on patient outcomes in HAVEN1","volume":"93","author":"Callaghan","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0109|cit109","first-page":"460","article-title":"A new treatment concept for haemophilia: safety, pharmacokinetics and pharmacodynamics of single i.v. and s.c. doses of a monoclonal anti-TFPI antibody in healthy males and haemophilia subjects","volume":"11 Suppl 2","author":"Chowdary","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors","volume":"1","author":"Cortesi","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0112|cit112","unstructured":"A clinical trial to study the effects of IB1001 in previously treated patients children with hemophilia B trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2011\/06\/001832"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0113|cit113","unstructured":"A clinical trial to see the effect of EMOCLOT drug (Kedrion factor VIII concentrate) in 50 previously treated haemophilia A children trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2012\/04\/002596"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0114|cit114","unstructured":"A clinical trial to study the effect of an unregistered drug in hemophilia B patients trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2013\/07\/003823"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0115|cit115","unstructured":"A post-marketing study receiving RIXUBIS as on-demand or prophylaxis under standard clinical practice in patients with Hemophilia B trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/07\/014754"},{"issue":"11","key":"10.1002\/14651858.CD014544.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"Ebbert","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"10.1002\/14651858.CD014544.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014544.pub3-BIB0119|cit119","first-page":"1","article-title":"Evaluation of safety and establishment of a PK\/PD relationship of concizumab in hemophilia a patients","volume":"1","author":"Eichler","year":"2017","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0120|cit120","unstructured":"Trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia a subjects www.clinicaltrials.gov\/show\/NCT02490787"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0121|cit121","unstructured":"A multi-centre trial evaluating efficacy and safety of prophylactic administration of concizumab in patients with severe haemophilia A without inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20170512002"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"w20422","DOI":"10.4414\/smw.2020.20422","article-title":"Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab","volume":"150","author":"Fontana","year":"2020","journal-title":"Swiss Medical Weekly"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2450\/2018.0272-17","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Trasfusione del sangue [Blood Transfusion]"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2450\/2019.0026-19","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Trasfusione del sangue [Blood Transfusion]"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/13543784.2020.1722999","article-title":"Investigational drugs to treat hemophilia","volume":"29","author":"Franchini","year":"2020","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0126|cit126","unstructured":"A research study of how a new medicine NNC0365-3769 (Mim8) works in the body of healthy people and patients with bleeding disorder trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-000465-20-ES"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0127|cit127","unstructured":"A research study investigating mim8 in people with haemophilia a www.clinicaltrials.gov\/show\/NCT04204408"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1111\/hae.14358","article-title":"Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: experience from a large haemophilia centre in the UK","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/hae.14183","article-title":"Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors - results from the HAVEN 2 study","volume":"1","author":"Mancuso","year":"2020","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0130|cit130","unstructured":"A study of emicizumab administered subcutaneously (SC) in pediatric participants with hemophilia A and Factor VIII (FVIII) inhibitors clinicaltrials.gov\/study\/NCT02795767"},{"issue":"11","key":"10.1002\/14651858.CD014544.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/17474086.2018.1531701","article-title":"Emicizumab for hemophilia A with factor VIII inhibitors","volume":"11","author":"Young","journal-title":"Expert Review of Hematology"},{"issue":"24","key":"10.1002\/14651858.CD014544.pub3-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"1","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0133|cit133","unstructured":"Phase III clinical study of emicizumab given every 4 weeks (Q4W) in patients with hemophilia A trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-163391"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2018-99-118132","article-title":"Preference for emicizumab over prior factor treatments: results from the HAVEN 3 and HAVEN 4 studies","volume":"132","author":"Jimenez-Yuste","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/jbm.S288283","article-title":"Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia A without inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"Journal of Blood Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"1","author":"Pipe","year":"2019","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0137|cit137","first-page":"328","article-title":"Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PWHA) with and without inhibitors: update from the haven 3 and haven 4 studies","volume":"3","author":"Skinner","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"Negrier","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood-2021-146009","article-title":"Emicizumab prophylaxis in persons with mild or moderate hemophilia A: results from the interim analysis of the HAVEN 6 study","volume":"138","author":"Negrier","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD014544.pub3-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0141|cit141","unstructured":"Prevention of bleeding in haemophilia A by prophylactic treatment with Nuwiq\u00ae trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN57549638"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0142|cit142","unstructured":"Phase III clinical trial of emicizumab given every 2 weeks and 4 weeks in hemophilia A pediatric patients without inhibitors (HOHOEMI) https:\/\/jrct.niph.go.jp\/latest-detail\/jRCT2080223654"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/jbm.S288283","article-title":"Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with Hemophilia A without Inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"Journal of Blood Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/hae.14372","article-title":"Adoption of emicizumab (Hemlibra\u00ae) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey","volume":"27","author":"Krumb","year":"2021","journal-title":"Haemophilia"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1056\/NEJMc1916299","article-title":"Emicizumab in hemophilia A","volume":"382","author":"Kruse-Jarres","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD014544.pub3-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Advances"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/hae.14143","article-title":"Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea","volume":"27","author":"Lee","year":"2021","journal-title":"Haemophilia"},{"issue":"14","key":"10.1002\/14651858.CD014544.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/DDDT.S167731","article-title":"Clinical evidence and safety profile of emicizumab for the management of children with hemophilia A","volume":"3","author":"Le Quellec","journal-title":"Drug Design, Development and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/bjh.16965","article-title":"Emicizumab for infants and children with haemophilia A","volume":"191","author":"Levy-Mendelovich","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/jbm.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"Journal of Blood Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14712598.2019.1626370","article-title":"Emicizumab for the prevention of bleeds in hemophilia A","volume":"19","author":"Mahlangu","year":"2019","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD014544.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/hae.14261","article-title":"Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data","volume":"27","author":"Misgav","year":"2021","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0156|cit156","unstructured":"Emicizumab PUPs and Nuwiq ITI Study https:\/\/clinicaltrials.gov\/study\/NCT04030052"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0157|cit157","unstructured":"Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER) https:\/\/clinicaltrials.gov\/study\/NCT05935358"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014544.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/hae.12980","article-title":"Updated results of an ongoing long-term phase 1\/2 study of emicizumab (ACE910) in hemophilia A patients with or without inhibitors","volume":"22","author":"Nogami","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14613","article-title":"Updated results of a long-term phase 1\/2 study of emicizumab (ACE910) in haemophilia A patients","volume":"176","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0160|cit160","first-page":"709","article-title":"A bispecific antibody mimicking factor VIII in hemophilia A therapy","volume":"1","author":"Nogami","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0161|cit161","first-page":"475","article-title":"Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors","volume":"1","author":"Nogami","year":"2019","journal-title":"Rinsho Ketsueki"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014544.pub3-BIB0162|cit162","first-page":"118","article-title":"Phase 1 and phase 1\/2 extension study of fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results in patients without inhibitors","volume":"23","author":"Chowdary","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0163|cit163","unstructured":"A phase 1 study of an investigational drug, ALN-AT3SC, in healthy volunteers and hemophilia a or b patients www.clinicaltrials.gov\/show\/NCT02035605"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0164|cit164","first-page":"76","article-title":"A subcutaneously administered investigational RNAi therapeutic, fitusiran (ALN-AT3), targeting antithrombin for treatment of hemophilia: interim results in patients with hemophilia a or b","volume":"22","author":"Pasi","year":"2016","journal-title":"Haemophilia"},{"issue":"23","key":"10.1002\/14651858.CD014544.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood.V126.23.551.551","article-title":"A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia a or b","volume":"126","author":"Pasi","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0166|cit166","first-page":"88","article-title":"Phase 1 and phase 1\/2 extension study of fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results in patients with inhibitors","volume":"23 Suppl 2","author":"Pasi","year":"2017","journal-title":"Haemophilia"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran - results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0168|cit168","first-page":"578","article-title":"Perioperative management of patients with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia","volume":"4","author":"Pasi","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia a or b with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0170|cit170","first-page":"20","article-title":"Management of bleed events in the phase 1 study of fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia in patients with and without inhibitors","volume":"23","author":"Rangarajan","year":"2017","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0171|cit171","first-page":"176","article-title":"A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: Interim phase 1 study results in patients with hemophilia A or B","volume":"13","author":"Sorensen","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.18553\/jmcp.2018.24.10-a.s1","article-title":"Economic impact model of delayed factor viii inhibitor development in persons with hemophilia a receiving emicizumab for the prevention of bleeding events","volume":"24:10-a Suppl","author":"Patel","year":"2018","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"12","key":"10.1002\/14651858.CD014544.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1080\/13696998.2019.1669614","article-title":"Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events","volume":"1","author":"Patel","year":"2019","journal-title":"Journal of Medical Economics"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1111\/hae.13822","article-title":"Safety and efficacy of emicizumab and other novel agents in newborns and infants","volume":"25","author":"Pierce","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/hae.14129","article-title":"Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France","volume":"27","author":"Polack","year":"2021","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0176|cit176","unstructured":"Preventing inhibitor recurrence indefinitely (PRIORITY) www.clinicaltrials.gov\/show\/NCT04621916"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0177|cit177","unstructured":"A study without drug intervention to observe bleeding episodes, factor VIII infusions, and patient-reported outcomes in individuals with severe hemophilia A trialsearch.who.int\/Trial2.aspx?TrialID=RBR-8z787r"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jth.15188","article-title":"Safety first: tracking adverse events associated with new therapies for people with hemophilia","volume":"19 Suppl 1","author":"Recht","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0179|cit179","unstructured":"Phase 1 study of ACE910 trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-121934"},{"issue":"22","key":"10.1002\/14651858.CD014544.pub3-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Advances"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1111\/hae.14364","article-title":"Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time","volume":"27","author":"Stonebraker","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1111\/hae.14159","article-title":"Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres","volume":"27","author":"Stonebraker","year":"2021","journal-title":"Haemophilia"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD014544.pub3-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/hae.14479","article-title":"Safety and efficacy of marstacimab for prevention of bleeding episodes in paediatric patients with severe haemophilia A or moderately severe to severe haemophilia A with or without inhibitors","volume":"28","author":"Teeter","year":"2022","journal-title":"Haemophilia"},{"issue":"22","key":"10.1002\/14651858.CD014544.pub3-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMc1712683","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Wada","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"e12571","DOI":"10.1002\/rth2.12571","article-title":"Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report","volume":"5","author":"Warren","year":"2021","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"105032","DOI":"10.1016\/j.ejps.2019.105032","article-title":"A systems pharmacokinetic\/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies","volume":"138","author":"Yuan","year":"2019","journal-title":"European Journal of Pharmceutical Sciences"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.18553\/jmcp.2020.19406","article-title":"Model of short- and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A","volume":"1","author":"Zhou","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0189|cit189","unstructured":"Research study to look at how well the drug concizumab works in your body if you have haemophilia without inhibitors www.clinicaltrials.gov\/show\/NCT04082429"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0190|cit190","unstructured":"Efficacy, safety, and pharmacokinetic study of prophylactic emicizumab versus no prophylaxis in hemophilia a participants www.clinicaltrials.gov\/show\/NCT03315455"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014544.pub3-BIB0191|cit191","first-page":"480","article-title":"A randomized, multicenter, open-label, phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)","volume":"4","author":"Wang","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0192|cit192","unstructured":"A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitors trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001048-24-IE"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0193|cit193","unstructured":"A research study investigating mim8 in adults and adolescents with haemophilia a with or without inhibitors www.clinicaltrials.gov\/show\/NCT05053139"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0194|cit194","unstructured":"Azvedo M Hemlibra named a breakthrough therapy for hemophilia A without inhibitors www.hemophilianewstoday.com\/2018\/04\/18\/hemlibra-named-breakthrough-therapy-in-hemophilia-a-without-inhibitors\/"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s13312-011-0098-6","article-title":"Rituximab","volume":"48","author":"Borker","year":"2011","journal-title":"Indian Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.12750","article-title":"A systematic review of definitions and reporting of bleeding outcome measures in haemophilia","volume":"21","author":"Chai-Adisaksopha","year":"2015","journal-title":"Haemophilia"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0197|cit197","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011441.pub2","article-title":"Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors","author":"Chai-Adisaksopha","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40265-018-0922-6","article-title":"Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab","volume":"78","author":"Chowdary","year":"2018","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0199|cit199","unstructured":"Covidence Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0200|cit200","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0201|cit201","first-page":"219","article-title":"Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?","volume":"1","author":"Ellsworth","journal-title":"Hematology, ASH Education Program"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0202|cit202","unstructured":"European Medicines Agency Serious adverse reaction https:\/\/www.ema.europa.eu\/en\/glossary\/serious-adverse-reaction"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1111\/j.1365-2516.2011.02687.x","article-title":"Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project","volume":"18","author":"Fischer","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0204|cit204","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfusion"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0205|cit205","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"12","key":"10.1002\/14651858.CD014544.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"Grade Guidelines 7: Rating the quality of evidence \u2013 inconsistency. GRADE Working Group","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD014544.pub3-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0208|cit208","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2\/"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0209|cit209","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0210|cit210","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0211|cit211","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003429.pub4","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B","author":"Iorio","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014544.pub3-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010810.pub3","article-title":"Rituximab for treating inhibitors in people with inherited severe hemophilia","author":"Jiang","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD014544.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/rth2.12195","article-title":"Hemophilia trials in the twenty-first century: defining patient important outcomes","volume":"3","author":"Konkle","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0215|cit215","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"Journal of Blood Medicine"},{"issue":"9","key":"10.1002\/14651858.CD014544.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors: HAVEN 3 Study","volume":"379","author":"Mahlangu","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0049-3848(10)70150-X","article-title":"EUHASS: the European Haemophilia Safety Surveillance system","volume":"127 Suppl 2","author":"Makris","year":"2011","journal-title":"Thrombosis Research"},{"issue":"23","key":"10.1002\/14651858.CD014544.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias - from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0220|cit220","volume-title":"User\u2019s Manual for the SF36v2 Health Survey","author":"Maruish","year":"2011"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/hae.13589","article-title":"Value of prophylaxis vs on-demand treatment: Application of a value framework in hemophilia","volume":"24","author":"Nugent","year":"2018","journal-title":"Haemophilia"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0224|cit224","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014201","article-title":"Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B","author":"Olasupo","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD014544.pub3-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.rpth.2023.102228","article-title":"Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study","volume":"7","author":"Olasupo","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0226|cit226","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0228|cit228","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0229|cit229","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"3","key":"10.1002\/14651858.CD014544.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/rth2.12212","article-title":"Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1","volume":"3","author":"Ribeiro","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0231|cit231","unstructured":"Rind D Agboola F Kumar V Segel C Chapman R Ellis A Emicizumab for hemophilia A with inhibitors: effectiveness and value - final evidence report The Institute for Clinical and Economic Review (ICER). https:\/\/icer.org\/assessment\/hemophilia-a-2018\/"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hae.12780","article-title":"Immune tolerance induction in patients with haemophilia A and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)","volume":"22","author":"Rocino","year":"2016","journal-title":"Haemophilia"},{"issue":"4","key":"10.1002\/14651858.CD014544.pub3-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jrsm.1259","article-title":"Methods for including information from multi-arm trials in pairwise meta-analysis","volume":"8","author":"R\u00fccker","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0234|cit234","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"21","key":"10.1002\/14651858.CD014544.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014544.pub3-BIB0236|cit236","doi-asserted-by":"crossref","unstructured":"Srivastava A Santagostino E Dougall A Kitchen S Sutherland M Pipe SW WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia Suppl 6 1 1 158","DOI":"10.1111\/hae.14046"},{"issue":"6","key":"10.1002\/14651858.CD014544.pub3-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5694\/mja15.01007","article-title":"Serious adverse event reporting in investigator-initiated clinical trials","volume":"204","author":"Wallace","journal-title":"Medical Journal of Australia"},{"issue":"4","key":"10.1002\/14651858.CD014544.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"1","key":"10.1002\/14651858.CD014544.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Therapeutic Advances in Hematology"},{"issue":"5","key":"10.1002\/14651858.CD014544.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"issue":"8","key":"10.1002\/14651858.CD014544.pub3-BIB0241|cit241","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014544","article-title":"Non-clotting factor therapies for preventing bleeds in people with hemophilia","author":"Olasupo","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:47:50Z","timestamp":1788500870000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014544.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":241,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014544.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}